Shares of 23andMe (ME) rose 21% to close at $13.32 apiece in their trading debut on the Nasdaq as the consumer genetic testing company became one of the latest companies to go public via SPAC deal.
The public debut comes after 23andMe and the special purpose acquisition company (SPAC) VG Acquisition Corp. announced a merger in February. The deal valued 23andMe’s outstanding shares of capital stock at $3.5 billion. The vast majority of shareholders of VG Acquisition Corp., which was founded…
Source link